At the Belgian Pharmaceutical Conference on the 17th April, we were fortunate enough to have Ingrid Maes, Director of Strategy & Operations, Pharma & Healthcare at PwC Belgium, present her talk, 'The Strategic Plan to Promote Clinical Trials in Belgium'.

Belgium is an important country for the conducting of clinical trials. However, this position is challenged from many sids and far from self-evident. In order to build a substantial clinical trials environment in Belgium, we need to understand the economic footprint of Belgium within the international clinical trials context. For The Initiative (ACRP, BAPU, BeAPP, FAGG and pharma.be), PwC gathered the insights and perspectives of key stakeholders in order to chart and assess the current situation and formulate clear, actionable recommendations on how a sustainable clinical trial environment in Belgium might be created.

To view Ingrid Maes' presentation, please click here.

Please click the link below to view the latest IFAPP World newsletter. Should you have any queries, please feel free to contact  This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

IFAPP World 2012

On behalf of the organizing committee, the Presidents of IFAPP and of the Spanish Association of Pharmaceutical Medicine (AMIFE) are pleased to inform you about the upcoming 16th ‘International Conference on Pharmaceutical Medicine’ – ICPM 2012 – to be held in Barcelona, Spain, from Wednesday through Friday 14th-16th November 2012.

ICPM 2012 is jointly organized by IFAPP and AMIFE. To find out more, please click here.

Dr Jan Van Emelen, Innovation Director at Neutral Mutualities presented on “Mutualities and pharmaceutical industry: a new relationship?”

On Friday 3rd March, Dr Jan Van Emelen, Innovation Director at Neutral Mutualities presented on “Mutualities and pharmaceutical industry: a new relationship?”. Access to new, often very expensive medications is a hot topic and our speaker discussed the role of the mutualities in this process, using new models for disease management. He shared ideas on our potential interaction with this process as pharmaceutical physicians.

To view this presentation, please click here.

If you should have any queries regarding the topic, please feel free to contact  This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

We are very pleased to inform you about the Belgian Regulatory Affairs Society's 1^st info-session of the year:

Challenges and opportunities in Paediatric development

The conference will clarify us on two main topics related to Paediatric development.

This afternoon session starts with a lesson for the future by analyzing the past. Five years after the implementation of the Paediatric regulation, the time has come to make an intermediate analysis. We will hear first-hand about the extensive experience of the PDCO (EMA) and have an actualised viewpoint on how the Paediatric Committee plans to continue their effort in the future.